While abortion medication remains available, Planned Parenthood Action Fund of New Jersey cautions against future attacks

TRENTON, N.J. — Today, in its decision in Food and Drug Administration (FDA) v. Alliance for Hippocratic Medicine, the U.S. Supreme Court upheld access to mifepristone, the primary drug used for medication abortions. While access to medication abortion remains unchanged for now, the case is returned to district court, and this attack on medication may continue.

Today’s decision comes from the same court that decimated abortion access across the country when they overturned Roe v. Wade in June 2022. Attacks on abortion do not end with this decision. In fact, there is still one more abortion-related decision expected in the days to come – and less than two years after Dobbs and the devastation that the court allowed to happen, the court is absolutely still making decisions that will affect our bodies, lives, and futures.

In response to today’s ruling, Kaitlyn Wojtowicz, Senior Vice President of Public Affairs with Planned Parenthood Action Fund of New Jersey, issued the following statement:
 
“While today's U.S. Supreme Court decision does not impact access to medication abortion, we experience only a tempered sense of relief, mindful of the uncertain future we face. We have watched our rights wither in the dark shadow cast by the Dobbs decision and, as a result, we are in the midst of a national reproductive health crisis.

“As the White House and Congress hang in the balance this November, so too does the future of reproductive health and rights. With looming federal threats to the rights we cherish here in New Jersey, it is imperative that our legislators address the diverse needs and rights of New Jerseyans seeking the full spectrum of reproductive health services. We must fortify protections for bodily autonomy and guard against future national assaults on our rights.”